IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd EBT Margin for the year ending December 31, 2023: -453.76%

IceCure Medical Ltd EBT Margin is -453.76% for the year ending December 31, 2023, a 17.55% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

IceCure Medical Ltd EBT Margin for the year ending December 31, 2022 was -550.34%, a -130.15% change year over year.
IceCure Medical Ltd EBT Margin for the year ending December 31, 2021 was -239.13%, a -108.24% change year over year.
IceCure Medical Ltd EBT Margin for the year ending December 31, 2020 was -114.83%, a 60.13% change year over year.
IceCure Medical Ltd EBT Margin for the year ending December 31, 2019 was -288.00%, a 12.65% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years